Core Viewpoint - The company, Maider Medical Equipment Co., Ltd., is holding an investor briefing on November 19, 2025, to discuss its Q3 2025 financial results and address investor inquiries [2][3][4]. Group 1: Meeting Details - The investor briefing is scheduled for November 19, 2025, from 13:00 to 14:00 [5]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][5]. - Investors can submit questions from November 12 to November 18, 2025, through the Roadshow Center website or via the company's email [2][4]. Group 2: Company Representatives - The meeting will feature key company representatives including Chairman and General Manager Mr. Lin Junhua, Secretary of the Board Mr. Lin Dong, and Financial Officer Mr. Lin Junhui [4][6]. - Independent Director Mr. He Tao will also be present, although attendance may vary due to special circumstances [4]. Group 3: Post-Meeting Information - After the investor briefing, participants can access the meeting's details and main content through the Shanghai Stock Exchange Roadshow Center [6].

Core Insights - The stock of Maide Medical (688310) closed at 17.37 yuan on November 10, 2025, with a rise of 2.24% and a trading volume of 39,500 hands, resulting in a transaction amount of 67.74 million yuan [1] Financial Performance - For the first three quarters of 2025, Maide Medical reported a main business revenue of 225 million yuan, an increase of 2.31% year-on-year, and a net profit attributable to shareholders of 8.84 million yuan, up 15.82% year-on-year [3] - In Q3 2025, the company achieved a single-quarter main business revenue of 83.64 million yuan, a year-on-year increase of 54.38%, and a net profit attributable to shareholders of 2.79 million yuan, up 224.07% year-on-year [3] - The company's gross profit margin stands at 40.19%, while the net profit margin is -2.43% [3] Market Position - Maide Medical's total market capitalization is 2.887 billion yuan, with a net asset value of 840 million yuan and a net profit of 8.84 million yuan [3] - The company has a price-to-earnings ratio (P/E) of 245.05, which is significantly higher than the industry average of 142.9 [3] - In terms of industry ranking, Maide Medical is positioned 219th in total market value and 200th in net assets among 270 companies in the specialized equipment industry [3] Capital Flow Analysis - On November 10, 2025, the net outflow of main funds was 2.65 million yuan, accounting for 3.92% of the total transaction amount, while retail investors saw a net inflow of 6.06 million yuan, representing 8.94% of the total transaction amount [1][2] - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net outflows from main and speculative funds on several days [2]

证券代码：688310 证券简称：迈得医疗 公告编号：2025-046 迈得医疗工业设备股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 投资者可于 2025 年 11 月 12 日（星期三）至 11 月 18 日（星期二）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （zq@maiderchina.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 迈得医疗工业设备股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 19 日（星期三） 13:00-14:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 202 ...

Market Overview - The automation equipment sector experienced a decline of 1.41% on November 7, with Mai De Medical leading the losses [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - Notable gainers in the automation equipment sector included: - Kaidi Co., Ltd. (605288) with a closing price of 95.51, up 4.78% [1] - Xinjie Electric (603416) with a closing price of 64.09, up 3.12% [1] - Haiteng Co., Ltd. (603283) with a closing price of 50.20, up 2.95% [1] - Major decliners included: - Mai De Medical (688310) with a closing price of 16.99, down 7.51% [2] - Weichuang Electric (688698) with a closing price of 77.03, down 6.40% [2] - Changfu Co., Ltd. (920396) with a closing price of 35.47, down 5.79% [2] Capital Flow - The automation equipment sector saw a net outflow of 855 million yuan from institutional investors, while retail investors contributed a net inflow of 490 million yuan [2] - The capital flow for specific stocks showed: - Kaidi Co., Ltd. (605288) had a net inflow of 38.31 million yuan from institutional investors [3] - Xinyu Laser (301021) had a net inflow of 32.02 million yuan from institutional investors [3] - However, Mai De Medical (688310) experienced a net outflow of 89.85 million yuan from retail investors [3]

Group 1 - The company held its first extraordinary general meeting of shareholders on October 30, 2025, where it approved the cancellation of the supervisory board, adjustment of the number of directors, and amendments to the Articles of Association [1][13] - The company elected Mr. Xie Yunbo as the employee representative director of the fifth board of directors during the employee representative meeting held on the same day [1][4] - The employee representative director will serve alongside the directors elected at the 2024 annual general meeting, with a term lasting until the end of the fifth board's term [1] Group 2 - The fifth board of directors' sixth meeting was also held on October 30, 2025, immediately following the extraordinary general meeting [5][7] - The meeting was attended by all eight directors, and the election of the chairman, Mr. Lin Junhua, as the legal representative of the company was approved [8][9] - The audit committee members and the convener were confirmed, with Ms. Zhang Yinghui serving as the convener [10][11] Group 3 - The extraordinary general meeting adopted several governance-related resolutions, including the revision and establishment of various governance systems [16][17] - All resolutions presented at the extraordinary general meeting were approved, with some requiring a two-thirds majority [18][19] - The meeting was witnessed by a law firm, confirming that all procedures and resolutions were in compliance with relevant laws and regulations [19]

Core Viewpoint - The recent performance of Maide Medical (688310) shows a decline in stock price and mixed financial results, with a notable increase in net profit but a significant drop in non-recurring net profit [1][3]. Stock Performance - As of October 31, 2025, Maide Medical's stock closed at 19.33 yuan, down 7.51% from the previous week [1]. - The stock reached a peak of 21.44 yuan on October 27 and a low of 18.76 yuan on October 30 [1]. - The company's current market capitalization is 3.213 billion yuan, ranking 69th out of 78 in the automation equipment sector and 4400th out of 5163 in the A-share market [1]. Shareholder Changes - As of September 30, 2025, the number of shareholders increased to 4528, up by 723 or 19.0% from June 30 [2]. - The average number of shares held per shareholder decreased from 43,700 to 36,700 shares, with an average holding value of 736,000 yuan [2]. Financial Performance - For Q3 2025, Maide Medical reported a main revenue of 225 million yuan, a year-on-year increase of 2.31% [3]. - The net profit attributable to shareholders was 8.8367 million yuan, up 15.82% year-on-year [3]. - The non-recurring net profit was -1.2785 million yuan, a significant decline of 526.58% year-on-year [3]. - In Q3 alone, the main revenue was 83.643 million yuan, reflecting a 54.38% year-on-year increase [3]. - The net profit for Q3 was 2.7916 million yuan, a substantial increase of 224.07% year-on-year [3]. - The non-recurring net profit for Q3 was 1.2364 million yuan, up 118.23% year-on-year [3]. - The company's debt ratio stands at 29.86%, with investment income of 167,600 yuan and financial expenses of -523,600 yuan, while the gross profit margin is 40.19% [3]. Company Announcements - On October 27, 2025, Maide Medical's fifth supervisory board meeting approved the Q3 report and the postponement of fundraising projects, confirming that the delay would not harm the company's or shareholders' interests [3]. - The "Annual Production of 35 Sets of Drug-Device Combination Intelligent Equipment Expansion Project" has been postponed to November 2026 due to production layout adjustments and equipment debugging, with a cumulative investment of 37.9365 million yuan, representing 59.08% of the planned investment [3]. Legal Opinions - On October 30, 2025, Maide Medical held its first extraordinary general meeting of 2025, where 13 resolutions, including changes to the supervisory board and amendments to the articles of association, were approved [4]. - The meeting had 18 attendees representing 66.7103% of the voting shares, and the legal opinion confirmed the legality and validity of the meeting procedures and resolutions [4].

Core Viewpoint - The stock of Maide Medical (688310) has shown a slight increase of 1.9% on October 31, 2025, closing at 19.33 yuan, with notable fluctuations in capital flow indicating mixed investor sentiment [1][2]. Financial Performance - For the first three quarters of 2025, Maide Medical reported a main revenue of 225 million yuan, a year-on-year increase of 2.31%, and a net profit attributable to shareholders of 8.84 million yuan, up 15.82% year-on-year [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 83.64 million yuan, reflecting a significant year-on-year increase of 54.38%, and a net profit of 2.79 million yuan, which is a remarkable rise of 224.07% year-on-year [3]. Capital Flow Analysis - On October 31, 2025, the net outflow of main funds was 1.87 million yuan, accounting for 3.32% of the total transaction amount, while retail investors saw a net inflow of 664,600 yuan, representing 1.18% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with significant net inflows and outflows from different investor categories [2]. Industry Comparison - Maide Medical's total market value stands at 3.213 billion yuan, which is below the industry average of 7.798 billion yuan, ranking 205th out of 269 in the specialized equipment industry [3]. - The company's price-to-earnings ratio (P/E) is 272.7, significantly higher than the industry average of 146.16, indicating a potential overvaluation compared to peers [3]. Company Overview - Maide Medical specializes in the research, production, sales, and service of medical consumables and intelligent equipment, integrating technology in medical device processes, automation, and software to provide comprehensive solutions for medical consumable manufacturers [3].

Core Viewpoint - Midea Medical, established in 2003 and listed in 2019, specializes in the research, production, and sales of medical consumables and intelligent equipment, holding several patents in the field [1]. Group 1: Business Performance - For Q3 2025, Midea Medical reported revenue of 225 million yuan, ranking 21st among 25 companies in the industry, with the industry leader achieving 3.653 billion yuan [2]. - The net profit for the same period was -5.46 million yuan, placing the company 18th in the industry, while the top performer reported a net profit of 417 million yuan [2]. Group 2: Financial Ratios - As of Q3 2025, Midea Medical's debt-to-asset ratio was 29.86%, lower than the industry average of 35.98% [3]. - The gross profit margin for Q3 2025 was 40.19%, which is above the industry average of 33.21% [3]. Group 3: Executive Compensation - The chairman, Lin Junhua, received a salary of 1.3803 million yuan in 2024, an increase of 909,300 yuan from the previous year [4]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 19% to 4,528, while the average number of shares held per shareholder decreased by 15.97% to 36,700 shares [5]. Group 5: Future Outlook - According to Guosheng Securities, Midea Medical's performance in the first half of 2025 declined due to fluctuations in downstream demand, but showed significant improvement in Q2 [6]. - The company has a strong order backlog for new products, with 21 units of drug-device combination products expected to drive growth [6]. - Revenue projections for 2025 to 2027 are 501 million, 606 million, and 734 million yuan, with corresponding net profits of 80 million, 108 million, and 131 million yuan, indicating substantial growth [6].

Core Viewpoint - On October 30, 2025, the company will hold a staff representative meeting where Mr. Xie Yunbo has been elected as the employee representative director of the fifth board of directors through democratic discussion and voting by the attending employee representatives [1] Group 1 - The company announced the date of the staff representative meeting as October 30, 2025 [1] - Mr. Xie Yunbo was elected as the employee representative director [1] - The election process involved democratic discussion and voting among employee representatives [1]

证券代码：688310 证券简称：迈得医疗 公告编号：2025-044 迈得医疗工业设备股份有限公司 董事会 迈得医疗工业设备股份有限公司 关于选举第五届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迈得医疗工业设备股份有限公司（以下简称"公司"）于2025年10月30日召开 2025年第一次临时股东大会，审议通过了《关于取消监事会、调整董事会人数、 修订〈公司章程〉并办理工商变更登记的议案》。根据修订后的《公司章程》， 公司董事会设职工代表董事1名，由公司职工代表大会、职工大会或者其他形式 民主选举产生。 公司于2025年10月30日召开职工代表大会，经与会职工代表民主讨论、表决， 选举谢云波先生（简历见附件）为公司第五届董事会职工代表董事。本次职工代 表大会选举产生的职工代表董事，将与公司2024年年度股东大会选举产生的董事 共同组成公司第五届董事会，任期自本次职工代表大会审议通过之日起至第五届 董事会任期届满之日止。 上述职工代表董事符合《公司法》等法律法规和《公司章程》规定的任职条 件。 ...